Despite the criticism Myriad Genetics receives for its business practices regarding BRCA testing, the company has stayed on message about two things. One, that its exclusive licenses and patents on BRCA 1 and BRCA 2 mutations, which essentially give it a monopoly over the BRCA testing market for hereditary breast and ovarian cancer, is good for business. And two, that the enforcement of its IP rights hasn't been harmful for patients or for researchers looking to develop better tests.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.